CJC-1295 and Ipamorelin UK 2026 Research Reference: Mechanism, Combined Protocol, Pharmacokinetics and Study Design

Last updated: April 2026 · UK research-grade reference · For laboratory research use only — not for human consumption

Table of Contents

• 1. Overview — why CJC-1295 and ipamorelin are paired
• 2. Receptor pharmacology: two pathways, one outcome
• 3. CJC-1295 structure and DAC variant
• 4. Ipamorelin structure and selectivity
• 5. Synergy mechanism at the somatotroph
• 6. Pharmacokinetics compared
• 7. Combined protocol design
• 8. Preserving GH pulsatility — why it matters
• 9. Hormonal selectivity vs sermorelin and GHRP-6
• 10. Safety profile and side-effect signals
• 11. Reconstitution, storage and stability
• 12. Research applications
• 13. UK research-grade sourcing standards
• FAQ
• References

1. Overview — why CJC-1295 and ipamorelin are paired

The growth-hormone-secretagogue research space divides into two receptor classes: GHRH receptor (GHRHR) agonists and ghrelin receptor (GHSR-1a) agonists. Both classes stimulate GH release from anterior pituitary somatotrophs, but via distinct intracellular signalling pathways. The combined-stack rationale — GHRH analogue plus ghrelin receptor agonist — was established in the 1990s in studies using GHRH(1-29) plus GHRP-6 or hexarelin, which demonstrated supra-additive (not merely additive) GH release.

CJC-1295 and ipamorelin represent the modern selective versions of this combination: CJC-1295 is the most pharmacokinetically stable GHRH analogue, and ipamorelin is the most receptor-selective ghrelin-mimetic without cortisol or prolactin elevation. For UK laboratory research into growth-hormone pulse biology, IGF-1 induction, or somatotroph receptor pharmacology, this pair is the reference combination.

2. Receptor pharmacology: two pathways, one outcome

GHRH receptor (GHRHR): Class B GPCR, expressed primarily on anterior pituitary somatotrophs. Signals via Gαs → adenylyl cyclase → cAMP → PKA → CREB phosphorylation → GH1 transcription and GH vesicle exocytosis. CJC-1295 binds here.

Ghrelin receptor (GHSR-1a): Class A GPCR, expressed on somatotrophs, hypothalamic neurons, and peripherally in gastric mucosa, pancreas, and cardiovascular tissue. Signals via Gαq → PLC → IP₃/DAG → Ca²⁺ release and PKC activation. Ipamorelin binds here.

At the somatotroph, GHRHR activation primarily drives transcriptional and secretory priming via cAMP, while GHSR-1a activation primarily drives immediate Ca²⁺-dependent exocytosis. Co-activation produces GH pulses with both larger amplitude and greater secretory reserve than either pathway alone.

3. CJC-1295 structure and DAC variant

CJC-1295 is derived from human GHRH(1-29), the smallest biologically active fragment of GHRH. Four amino acid substitutions (D-Ala²→stabilise N-terminus against DPP-4; Gln⁸, Ala¹⁵, Leu²⁷) confer increased intrinsic stability and receptor affinity.

CJC-1295 “no DAC” (also called Modified GRF 1-29, mod-GRF 1-29): The 29-amino-acid peptide alone. Half-life approximately 30 minutes. Produces rapid, defined GH pulses. Preserves physiological pulsatility when dosed 1-3× daily.

CJC-1295 “with DAC”: Adds a maleimidopropionyl-lysine tail that reacts covalently with circulating albumin in plasma. The albumin conjugate has a half-life of approximately 8 days. Produces sustained GHRH-receptor activation. Does not preserve pulsatility — somatotroph stimulation is tonic.

Research protocols that aim to model physiological GH release use CJC-1295 no-DAC; protocols that aim to produce sustained elevation of IGF-1 or model pharmacological overdrive use CJC-1295 with DAC.

4. Ipamorelin structure and selectivity

Ipamorelin is a pentapeptide — Aib-His-D-2-Nal-D-Phe-Lys-NH₂ — designed at Novo Nordisk in the 1990s as a selective ghrelin receptor agonist without cross-reactivity at the receptors responsible for cortisol and prolactin release.

Key pharmacological features:

• GHSR-1a selectivity: comparable GH-releasing potency to hexalrelin and GHRP-6 but without the cortisol, ACTH or prolactin elevation those peptides produce
• Half-life: approximately 2 hours (plasma)
• No appetite stimulation at standard research doses (unlike GHRP-6, which is a potent orexigen via the hypothalamic ghrelin circuit)
• No significant effect on insulin sensitivity at research doses

Ipamorelin’s clean selectivity profile is the reason it is the preferred ghrelin-mimetic for research stacks — it isolates the ghrelin-receptor contribution to GH release without confounding effects on the HPA axis or lactotrophs.

5. Synergy mechanism at the somatotroph

Co-administration of GHRH analogue plus ghrelin-receptor agonist produces 2-5× greater peak GH release than the sum of each peptide alone. The mechanism involves:

1. Converging second-messenger pathways: cAMP (from GHRHR) and Ca²⁺ (from GHSR-1a) both potentiate GH vesicle exocytosis; their convergence is synergistic, not additive.
2. Suppression of somatostatin: GHSR-1a activation at hypothalamic sites suppresses periventricular somatostatin neurons, removing the tonic brake on GH release. CJC-1295 alone does not do this.
3. Priming of somatotroph secretory reserve: CJC-1295’s cAMP signalling increases GH1 transcription and vesicle loading; subsequent ipamorelin-driven exocytosis releases this larger reserve.

The practical research consequence: a combined protocol produces not only larger but more reproducible GH pulses than either peptide alone.

6. Pharmacokinetics compared

CJC-1295 no-DAC (mod-GRF 1-29):

• Molecular weight: 3367.91 Da (30 aa after modifications including C-terminal NH₂)
• Half-life: 25-30 min (SC)
• Tmax: 10-20 min
• Duration of GH-releasing effect: 60-90 min

CJC-1295 with DAC:

• Molecular weight: 3647.20 Da (as synthesised); effective MW as albumin-DAC conjugate ~70,000 Da
• Half-life: ~8 days (as albumin conjugate)
• Steady-state reached: 3-4 weeks of weekly dosing
• Duration of GH-releasing effect: continuous at steady state

Ipamorelin:

• Molecular weight: 711.86 Da (pentapeptide + N-terminal Aib)
• Half-life: 2 hours
• Tmax: 15-30 min SC
• Duration of GH-releasing effect: 2-3 hours

7. Combined protocol design

Standard UK laboratory research protocols using the CJC-1295 + ipamorelin combination fall into two designs:

Pulsatile design (no-DAC + ipamorelin):

• CJC-1295 no-DAC: 100 µg SC
• Ipamorelin: 100-200 µg SC
• Timing: co-administered, 1-3× daily
• Typical pattern: morning, mid-afternoon, and/or pre-bed
• Duration: 8-12 week study blocks
• Rationale: models physiological pulsatile GH release with amplified pulses

Sustained design (with-DAC + ipamorelin):

• CJC-1295 with DAC: 1-2 mg SC weekly
• Ipamorelin: 200-300 µg SC, 1-3× daily
• Rationale: sustained GHRH-receptor priming plus pulsatile ghrelin-receptor activation
• Produces chronically elevated IGF-1 with retained pulse character
• Duration: 8-12 week study blocks

Dose-response data in healthy adults show approximately linear IGF-1 response up to CJC-1295 2 mg weekly; plateau above 2 mg. Ipamorelin dose-response plateaus at approximately 300 µg per administration.

8. Preserving GH pulsatility — why it matters

Physiological GH release is strongly pulsatile, with 5-8 pulses per 24 hours, peak concentrations during the first hours of sleep, and near-undetectable trough concentrations between pulses. The pulsatility itself is biologically important:

• Downstream signalling (JAK2-STAT5, MAPK) is pulse-encoded; continuous GH signalling produces different transcriptional outputs than pulsatile signalling
• Peripheral GH receptor sensitivity is maintained by trough periods; continuous stimulation produces receptor desensitisation
• Sex-dimorphic gene expression in liver is pulsatility-dependent

Research designs that want to preserve these features use CJC-1295 no-DAC; designs that accept desensitisation as a variable or deliberately model pharmacological overdrive use CJC-1295 with DAC.

9. Hormonal selectivity vs sermorelin and GHRP-6

Sermorelin: GHRH(1-29), the unmodified native fragment. Half-life 10-20 minutes. No DAC variant. Largely superseded by CJC-1295 no-DAC in research use because the four CJC substitutions produce longer half-life and greater receptor affinity without loss of selectivity.

GHRP-6: First-generation ghrelin-receptor agonist. Potent GH releaser but also potent orexigen (strong appetite stimulation), moderate cortisol and prolactin elevation. Suitable for appetite research but inferior to ipamorelin for clean growth-hormone secretagogue studies.

GHRP-2: Intermediate selectivity — better than GHRP-6 but less selective than ipamorelin.

Hexarelin: Most potent ghrelin-receptor agonist but greatest cortisol and prolactin cross-reactivity. Declining use in contemporary research.

MK-677 (ibutamoren): Orally bioavailable non-peptide ghrelin-receptor agonist. Useful where oral administration is required; produces greater tonic activation than injectable ghrelin-mimetics. Covered in detail in a separate reference article.

10. Safety profile and side-effect signals

The combination is well-characterised in the research literature with a defined side-effect profile:

• Injection-site reactions: 3-8%, typically mild erythema and transient induration
• Transient hypoglycaemia: 1-3%, related to the post-pulse IGF-1 insulin-mimetic effect; mitigated by food near dosing
• Transient fluid retention: 5-10%, peripheral oedema or mild facial fullness, usually resolves after 2-4 weeks of adaptation
• Carpal tunnel symptoms: <5%, dose-related, reversible on dose reduction
• Headache: 5-10%, typically transient at initiation
• Injection-site lipohypertrophy: <1% with appropriate site rotation

Notable absences from the ipamorelin profile: cortisol elevation, prolactin elevation, significant appetite stimulation — the features that differentiate ipamorelin from GHRP-6 and hexarelin.

11. Reconstitution, storage and stability

CJC-1295 no-DAC (typical 2 mg vial): reconstitute with 2 mL bacteriostatic water → 1 mg/mL. At 100 µg per administration, 0.1 mL (10 units on an insulin syringe).

CJC-1295 with DAC (typical 2 mg vial): reconstitute with 2 mL bacteriostatic water → 1 mg/mL. At 1-2 mg weekly, 1-2 mL per dose.

Ipamorelin (typical 5 mg vial): reconstitute with 2.5 mL bacteriostatic water → 2 mg/mL. At 200 µg per administration, 0.1 mL (10 units).

All three peptides are stable after reconstitution at 2-8°C for 30-45 days. Protect from freezing and direct light. Do not mix in the same syringe with non-compatible co-formulations; co-administration is typically done as two separate injections at adjacent subcutaneous sites.

12. Research applications

Established UK laboratory research applications for the CJC-1295 + ipamorelin combination:

• Pulsatile GH release dynamics and pulse-amplitude modelling
• IGF-1 generation and time-course studies
• Somatotroph receptor pharmacology, desensitisation and re-sensitisation kinetics
• Sex-dimorphic GH pulse pattern studies in preclinical models
• Hypothalamic-pituitary axis GH-branch stimulation tests
• Benchmarking arm in novel growth-hormone-secretagogue compound development
• Tissue-specific IGF-1 response studies (hepatic, muscle, cartilage)
• Body-composition research in rodent and non-human primate models

13. UK research-grade sourcing standards

Both peptides should be sourced with full documentation:

• ≥98% HPLC purity (≥99% is the emerging 2026 standard)
• Mass spectrometry identity confirmation (CJC-1295 no-DAC 3367.91 Da; CJC-1295 with-DAC 3647.20 Da; ipamorelin 711.86 Da)
• Batch-specific Certificate of Analysis
• Endotoxin quantification
• Residual TFA analysis
• Lyophilised powder with cold-chain shipping

A quality-control specific note for CJC-1295 with DAC: the maleimidopropionyl-lysine tail is the most difficult synthetic step and the most common site of batch-to-batch variance. A high-quality COA should specifically confirm DAC attachment yield and absence of des-DAC parent peptide.

FAQ

Should I use CJC-1295 with or without DAC?
Use no-DAC to preserve pulsatility and model physiological GH release; use with-DAC to produce sustained IGF-1 elevation. Most UK laboratory protocols default to no-DAC because pulsatility is biologically relevant.

Is the synergy real?
Yes. Paired-dose studies consistently show 2-5× greater GH pulse amplitude than either peptide alone, confirmed across healthy adult and preclinical cohorts since the late 1990s.

Does ipamorelin elevate cortisol?
No, at standard research doses. Ipamorelin was specifically designed to lack the cortisol and prolactin cross-reactivity of GHRP-6. In direct head-to-head studies, ipamorelin produces no significant elevation of cortisol or prolactin even at supra-physiological GH-releasing doses.

Does ipamorelin cause appetite stimulation?
No, at standard research doses. This differentiates it sharply from GHRP-6.

How long before IGF-1 elevation is measurable?
With a pulsatile protocol: IGF-1 begins to rise within 48-72 hours; stable elevation by 2-3 weeks. With DAC protocol: similar time course but larger magnitude.

Is there a tachyphylaxis issue?
Mild. Over 8-12 weeks of continuous dosing, GH pulse amplitude per administration decreases approximately 20-30%. Cycling protocols (8 weeks on, 4 weeks off) are commonly used to preserve somatotroph responsiveness.

Can the pair be combined with tesamorelin or sermorelin?
Mechanistically redundant with tesamorelin and sermorelin (all three are GHRHR agonists). No added benefit expected. The rational combinations are CJC-1295 (or tesamorelin, or sermorelin) + ipamorelin (or another ghrelin-mimetic).

References

1. Teichman SL et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295 in healthy adults. J Clin Endocrinol Metab 2006;91:799–805.
2. Raun K et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol 1998;139:552–561.
3. Jimenez-Reina L et al. In vitro effects of ghrelin and GHRP-6 on somatotroph GH secretion. Endocrinology 2003;144:3336–3344.
4. Bowers CY. History of the development of GH-releasing peptides and analogues. Growth Horm IGF Res 2012;22:221–231.
5. Ionescu M, Frohman LA. Pulsatile secretion of growth hormone induced by the combination of a GH-releasing peptide and a GH-releasing hormone analog. J Clin Endocrinol Metab 2006;91:4792–4797.
6. Khorram O et al. Effects of aging on the pulsatile secretion of growth hormone and its response to GHRH. J Clin Endocrinol Metab 1997;82:1472–1479.
7. Kineman RD et al. Understanding the physiology of growth hormone-releasing hormone and growth hormone-releasing peptide action. Front Endocrinol 2011;2:24.
8. Howard AD et al. A receptor in pituitary and hypothalamus that functions in growth hormone release. Science 1996;273:974–977.
9. Camanni F, Ghigo E, Arvat E. Growth hormone-releasing peptides and their analogs. Front Neuroendocrinol 1998;19:47–72.
10. Sigalos JT, Pastuszak AW. The safety and efficacy of growth hormone secretagogues. Sex Med Rev 2018;6:45–53.

UK Research Cluster Hubs

• GLP-1 Research Hub
• Tirzepatide Hub
• Retatrutide Hub
• BPC-157 Research Hub
• TB-500 Research Hub
• Growth-Hormone Peptides Hub
• Research-Grade Buyer’s Guide

Disclaimer: All peptides referenced are sold strictly for in vitro laboratory research use. Not for human consumption, veterinary use, food additive, cosmetic, or household purpose. Nothing in this article is medical advice. UK researchers are responsible for compliance with the Human Medicines Regulations 2012 and Misuse of Drugs Regulations 2001 where applicable.